$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000091447523000011 Filed on February 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$420.4M	$412.0M	$1.489B
YoY Change	35.35%	32.05%	31.34%
Cost Of Revenue	$8.500M	$7.700M	$23.20M
YoY Change	84.78%	87.8%	62.24%
Gross Profit	$411.9M	$404.3M	$1.466B
YoY Change	34.61%	31.31%	30.94%
Gross Profit Margin	97.98%	98.13%	98.44%
Selling, General & Admin	$242.7M	$182.9M	$752.7M
YoY Change	20.93%	16.87%	29.04%
% of Gross Profit	58.92%	45.24%	51.36%
Research & Development	$139.5M	$118.0M	$463.8M
YoY Change	36.5%	35.01%	340.46%
% of Gross Profit	33.87%	29.19%	31.65%
Depreciation & Amortization	$4.100M	$4.400M	$15.10M
YoY Change	24.24%	46.67%	38.53%
% of Gross Profit	1.0%	1.09%	1.03%
Operating Expenses	$382.2M	$300.9M	$1.217B
YoY Change	26.18%	23.37%	17.99%
Operating Profit	-$114.2M	$103.4M	$249.0M
YoY Change	-3783.87%	61.56%	142.93%
Interest Expense	$1.100M	$14.50M	$7.100M
YoY Change	-57.69%	-35.56%	-72.48%
% of Operating Profit		14.02%	2.85%
Other Income/Expense, Net	$10.90M		-$35.10M
YoY Change	-40.44%		3090.91%
Pretax Income	-$103.3M	$117.9M	$213.9M
YoY Change	-582.71%	-954.35%	110.95%
Income Tax	-$26.70M	$28.90M	$59.40M
% Of Pretax Income		24.51%	27.77%
Net Earnings	-$76.60M	$89.00M	$154.5M
YoY Change	-651.08%	-1319.18%	72.43%
Net Earnings / Revenue	-18.22%	21.6%	10.38%
Basic Earnings Per Share	-$0.79		$1.61
Diluted Earnings Per Share	-$0.79	$0.88	$1.56
COMMON SHARES
Basic Shares Outstanding	96.59M shares	96.13M shares	95.80M shares
Diluted Shares Outstanding	97.10M shares		98.90M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$894.6M	$989.3M	$989.3M
YoY Change	34.55%	39.08%	39.08%
Cash & Equivalents	$103.8M	$262.9M	$262.9M
Short-Term Investments	$790.8M	$726.4M	$726.4M
Other Short-Term Assets	$113.2M	$79.10M	$79.10M
YoY Change	86.18%	73.85%	73.85%
Inventory	$33.40M	$35.10M	$35.10M
Prepaid Expenses
Receivables	$391.6M	$350.0M	$350.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.433B	$1.454B	$1.454B
YoY Change	40.72%	49.41%	49.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.80M	$58.60M	$145.6M
YoY Change	-1.72%	0.0%	-6.55%
Goodwill	$5.600M	$5.400M
YoY Change
Intangibles	$37.20M	$37.20M
YoY Change
Long-Term Investments	$380.3M	$401.5M	$401.5M
YoY Change	-39.85%	-35.7%	-35.7%
Other Assets	$24.90M	$25.00M	$330.9M
YoY Change	146.53%	468.18%	3.57%
Total Long-Term Assets	$927.0M	$915.2M	$915.2M
YoY Change	-17.7%	-16.78%	-16.78%
TOTAL ASSETS
Total Short-Term Assets	$1.433B	$1.454B	$1.454B
Total Long-Term Assets	$927.0M	$915.2M	$915.2M
Total Assets	$2.360B	$2.369B	$2.369B
YoY Change	10.04%	14.29%	14.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$355.7M	$347.6M	$235.7M
YoY Change	50.78%	53.94%	65.06%
Accrued Expenses	$17.60M	$17.40M	$129.3M
YoY Change	4.14%	5.45%	29.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$169.4M	$169.4M
YoY Change
Total Short-Term Liabilities	$374.1M	$537.7M	$537.7M
YoY Change	47.57%	118.76%	118.76%
LONG-TERM LIABILITIES
Long-Term Debt	$169.5M	$0.00	$0.00
YoY Change	-55.12%	-100.0%	-100.0%
Other Long-Term Liabilities	$41.30M	$29.70M	$123.2M
YoY Change	109.64%	141.46%	4.76%
Total Long-Term Liabilities	$41.30M	$29.70M	$123.2M
YoY Change	109.64%	141.46%	-72.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$374.1M	$537.7M	$537.7M
Total Long-Term Liabilities	$41.30M	$29.70M	$123.2M
Total Liabilities	$675.3M	$660.9M	$660.9M
YoY Change	-10.37%	-5.38%	-5.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$483.4M	-$406.8M
YoY Change	-11.69%	-36.02%
Common Stock	$2.171B	$2.123B
YoY Change	11.44%	5.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.685B	$1.708B	$1.708B
YoY Change
Total Liabilities & Shareholders Equity	$2.360B	$2.369B	$2.369B
YoY Change	10.04%	14.29%	14.29%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$76.60M	$89.00M	$154.5M
YoY Change	-651.08%	-1319.18%	72.43%
Depreciation, Depletion And Amortization	$4.100M	$4.400M	$15.10M
YoY Change	24.24%	46.67%	38.53%
Cash From Operating Activities	-$125.2M	$143.0M	$339.4M
YoY Change	209.14%	3304.76%	32.32%
INVESTING ACTIVITIES
Capital Expenditures	$8.500M	$1.800M	$16.50M
YoY Change	11.84%	-120.22%	-29.49%
Acquisitions			$42.70M
YoY Change
Other Investing Activities	-$33.60M	-$113.8M	-$160.6M
YoY Change	40.0%	-449.08%	50.37%
Cash From Investing Activities	-$42.10M	-$115.6M	-$177.1M
YoY Change	33.23%	-587.76%	36.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$44.70M
YoY Change			62.55%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.200M	24.60M	-$234.3M
YoY Change	34.43%	1266.67%	-955.11%
NET CHANGE
Cash From Operating Activities	-$125.2M	143.0M	$339.4M
Cash From Investing Activities	-$42.10M	-115.6M	-$177.1M
Cash From Financing Activities	$8.200M	24.60M	-$234.3M
Net Change In Cash	-$159.1M	52.00M	-$73.30M
YoY Change	141.06%	75.08%	-147.69%
FREE CASH FLOW
Cash From Operating Activities	-$125.2M	$143.0M	$339.4M
Capital Expenditures	$8.500M	$1.800M	$16.50M
Free Cash Flow	-$133.7M	$141.2M	$322.9M
YoY Change	177.96%	977.86%	38.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000914475
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P13Y7M
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-22705
CY2022	dei	Entity Registrant Name EntityRegistrantName	NEUROCRINE BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0525145
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	12780 El Camino Real,
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	617-7600
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	NBIX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	8097146859	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96587911	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	262900000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340800000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	726400000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	370500000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	350000000.0	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	185500000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	35100000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	30500000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	79100000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	45500000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1453500000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	972800000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	305900000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	315100000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	299400000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	560700000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	87000000.0	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97200000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Restricted EquitySecuritiesFvNiRestricted	102100000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni Restricted EquitySecuritiesFvNiRestricted	63700000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58600000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58600000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	37200000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25000000.0	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4400000	usd
CY2022Q4	us-gaap	Assets Assets	2368700000	usd
CY2021Q4	us-gaap	Assets Assets	2072500000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	347600000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	225800000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	169400000	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20700000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20000000.0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	537700000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	245800000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	335100000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93500000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105300000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29700000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12300000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	660900000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	698500000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96500000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96500000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94900000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94900000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2122400000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2011400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7900000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1700000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-406800000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-635800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1707800000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1374000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2368700000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2072500000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1488700000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1133500000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1045900000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23200000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14300000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10100000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	463800000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	328100000	usd
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	275000000.0	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	105300000	usd
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	164500000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	752700000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	583300000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	433300000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1239700000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1031000000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	882900000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	249000000.0	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	102500000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	163000000.0	usd
CY2022	us-gaap	Interest Expense InterestExpense	7100000	usd
CY2021	us-gaap	Interest Expense InterestExpense	25800000	usd
CY2020	us-gaap	Interest Expense InterestExpense	32800000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	30800000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	20900000	usd
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-17700000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-70000000.0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-18400000	usd
CY2022	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	11200000	usd
CY2021	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	3800000	usd
CY2020	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	12600000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35100000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1100000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-56300000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	213900000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	101400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	106700000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	59400000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11800000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300600000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	154500000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	89600000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	407300000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-2900000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9100000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3500000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	400000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	148300000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	86100000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	407700000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.61
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.56
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.16
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95800000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94600000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93100000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98900000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97900000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97800000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	636900000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	407300000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	400000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	100000000.0	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	47500000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29100000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1126200000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	89600000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3500000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	134200000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27500000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1374000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	154500000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6200000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	173100000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	44700000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1707800000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	154500000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	89600000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	407300000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	173100000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	134200000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	100000000.0	usd
CY2022	us-gaap	Depreciation Depreciation	15100000	usd
CY2021	us-gaap	Depreciation Depreciation	10900000	usd
CY2020	us-gaap	Depreciation Depreciation	8600000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	16200000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20000000.0	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1200000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1100000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1400000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	30800000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	20900000	usd
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-17700000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	19100000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4300000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-310700000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-70000000.0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-18400000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	4100000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	4400000	usd
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3700000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	162200000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28400000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30500000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2600000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2500000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10700000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	114600000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	56800000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26900000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets And Liabilities Net IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet	17200000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets And Liabilities Net IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet	9200000	usd
CY2020	us-gaap	Increase Decrease In Other Current Assets And Liabilities Net IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet	23600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	339400000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	256500000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	228500000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	621200000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	800100000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	735500000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	511000000.0	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	697900000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	750500000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	42700000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	7700000	usd
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	4600000	usd
CY2020	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16500000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23400000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177100000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-130200000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4100000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	44700000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27500000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29100000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	279000000.0	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	100000	usd
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	186900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-234300000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27400000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-157800000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1300000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-73300000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	153700000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74800000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	344000000.0	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190300000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115500000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270700000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	344000000.0	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190300000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	700000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1900000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1400000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23400000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12800000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6600000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	8600000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	11600000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	14400000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	5100000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	15300000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span>
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest Threshold Period Writeoff DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff	P90D
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	4700000	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2200000	usd
CY2022	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2020	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2021	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2022	us-gaap	Depreciation Depreciation	15100000	usd
CY2021	us-gaap	Depreciation Depreciation	10900000	usd
CY2020	us-gaap	Depreciation Depreciation	8600000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product sales for 2022 and approximately 95% of our accounts receivable balance as of December 31, 2022.</span></div>
CY2022	us-gaap	Advertising Expense AdvertisingExpense	149700000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	139800000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	64800000	usd
CY2022Q4	nbix	Potential Milestone Payments PotentialMilestonePayments	10800000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	735800000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	9400000	usd
CY2022Q4	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	726400000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	370600000	usd
CY2021Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2021Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	100000	usd
CY2021Q4	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	370500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	304500000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	200000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	5300000	usd
CY2022Q4	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	299400000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	563200000	usd
CY2021Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	0	usd
CY2021Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	2500000	usd
CY2021Q4	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	560700000	usd
CY2022Q4	nbix	Debt Securities Available For Sale Position Number Of Positions DebtSecuritiesAvailableForSalePositionNumberOfPositions	253	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	199	security
CY2022	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	5900000	usd
CY2021	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	8500000	usd
CY2020	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	11400000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1200000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17300000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21400000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7100000	usd
CY2021	us-gaap	Interest Expense InterestExpense	25800000	usd
CY2020	us-gaap	Interest Expense InterestExpense	32800000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	5200000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	200000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5400000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	37200000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	16300000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12000000.0	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11200000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5600000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3600000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17500000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	15700000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	35100000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	30500000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	124900000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	110500000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66300000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51900000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58600000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58600000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	72800000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	50600000	usd
CY2022Q4	nbix	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	131900000	usd
CY2021Q4	nbix	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	62700000	usd
CY2022Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	39100000	usd
CY2021Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	32400000	usd
CY2022Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	27500000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000000.0	usd
CY2021Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	28600000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	76300000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	51500000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	347600000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	225800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	262900000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340800000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	7800000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	270700000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	344000000.0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	154500000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	154500000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	89600000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	89600000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	407300000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	407300000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95800000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94600000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93100000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3100000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3300000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4700000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98900000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97900000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97800000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.61
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.56
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.16
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	173100000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	134200000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	173100000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	134200000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000000.0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	32.05
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.02
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.67
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7700000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	76.38
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2200000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	81.27
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	700000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	52.96
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	96.28
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9000000.0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.10
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	362800000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6000000.0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	72.27
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	281900000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39700000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	58000000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	40200000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37000000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20700000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23500000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	218000000.0	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	101400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	106700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4100000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	213900000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	101400000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	106700000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	21300000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	17100000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20300000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6300000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10100000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	37400000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6300000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10100000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	27500000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5900000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-287500000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5500000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-400000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-23200000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	22000000.0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5500000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-310700000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	59400000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11800000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300600000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	44900000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	22400000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	200000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	11800000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	6200000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	5500000	usd
CY2022	nbix	Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee	6500000	usd
CY2021	nbix	Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee	4800000	usd
CY2020	nbix	Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee	4900000	usd
CY2022	nbix	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Extinguishment Of Convertible Senior Notes EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes	12000000.0	usd
CY2021	nbix	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Extinguishment Of Convertible Senior Notes EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes	0	usd
CY2020	nbix	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Extinguishment Of Convertible Senior Notes EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2500000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-11300000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-6700000	usd
CY2022	nbix	Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost	9200000	usd
CY2021	nbix	Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost	7000000.0	usd
CY2020	nbix	Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost	3700000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1300000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3300000	usd
CY2022	nbix	Income Tax Reconciliation Expiration Of Tax Credits IncomeTaxReconciliationExpirationOfTaxCredits	0	usd
CY2021	nbix	Income Tax Reconciliation Expiration Of Tax Credits IncomeTaxReconciliationExpirationOfTaxCredits	600000	usd
CY2020	nbix	Income Tax Reconciliation Expiration Of Tax Credits IncomeTaxReconciliationExpirationOfTaxCredits	1100000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	29900000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	22000000.0	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	39000000.0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7400000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5000000.0	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-296300000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1300000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	500000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	59400000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11800000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	108900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	129700000	usd
CY2022Q4	nbix	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	91100000	usd
CY2021Q4	nbix	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	17900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	45900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	38900000	usd
CY2022Q4	nbix	Deferred Tax Assets Operating Leases Assets DeferredTaxAssetsOperatingLeasesAssets	26800000	usd
CY2021Q4	nbix	Deferred Tax Assets Operating Leases Assets DeferredTaxAssetsOperatingLeasesAssets	29300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	80700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	86100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	24900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	405700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	413800000	usd
CY2022Q4	nbix	Deferred Tax Liabilities Convertible Senior Notes DeferredTaxLiabilitiesConvertibleSeniorNotes	0	usd
CY2021Q4	nbix	Deferred Tax Liabilities Convertible Senior Notes DeferredTaxLiabilitiesConvertibleSeniorNotes	9900000	usd
CY2022Q4	nbix	Deferred Tax Liabilities Operating Leases Liabilities DeferredTaxLiabilitiesOperatingLeasesLiabilities	21000000.0	usd
CY2021Q4	nbix	Deferred Tax Liabilities Operating Leases Liabilities DeferredTaxLiabilitiesOperatingLeasesLiabilities	23300000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	11800000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	10700000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32800000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	43900000	usd
CY2022Q4	nbix	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	372900000	usd
CY2021Q4	nbix	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	369900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67000000.0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	305900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	315100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	305900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67000000	usd
CY2022Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	500000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	400000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	64600000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	60800000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	63900000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	4700000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	600000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	5700000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	15200000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4900000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3900000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	200000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1700000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	84500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	64600000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	60800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	74800000	usd
CY2022Q1	nbix	Lessee Operating Lease Option Term To Construct Fifth Building LesseeOperatingLeaseOptionTermToConstructFifthBuilding	P6Y
CY2022Q1	nbix	Rent Abatement Period RentAbatementPeriod	P10M
CY2022Q1	nbix	Lessee Operating Lease Monthly Base Rent Per Square Foot LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot	6	usd
CY2022Q1	nbix	Annual Rent Escalation Percentage AnnualRentEscalationPercentage	0.03
CY2022Q1	nbix	Number Of Renewal Options NumberOfRenewalOptions	2	renewaloption
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	16300000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	15300000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	10100000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	16900000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	12600000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	8600000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17900000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17400000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15900000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	15700000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	16000000.0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	54400000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	137300000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	26400000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	110900000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17400000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93500000	usd
CY2022Q4	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo	17200000	usd
CY2022Q4	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree	33300000	usd
CY2022Q4	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour	41900000	usd
CY2022Q4	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Five NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive	479700000	usd
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	10300000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8100000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6700000	usd

Files In Submission

Name	View Source	Status
0000914475-23-000011-index-headers.html	Edgar Link	pending
0000914475-23-000011-index.html	Edgar Link	pending
0000914475-23-000011.txt	Edgar Link	pending
0000914475-23-000011-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nbix-20221231.htm	Edgar Link	pending
nbix-20221231.xsd	Edgar Link	pending
nbix-20221231_g1.jpg	Edgar Link	pending
nbix-20221231_g2.jpg	Edgar Link	pending
nbix-20221231_g3.jpg	Edgar Link	pending
q4-2022xexhibit211.htm	Edgar Link	pending
q4-2022xexhibit231.htm	Edgar Link	pending
q4-2022xexhibit311.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nbix-20221231_cal.xml	Edgar Link	unprocessable
nbix-20221231_def.xml	Edgar Link	unprocessable
nbix-20221231_lab.xml	Edgar Link	unprocessable
nbix-20221231_pre.xml	Edgar Link	unprocessable
nbix-20221231_htm.xml	Edgar Link	completed
q4-2022xexhibit312.htm	Edgar Link	pending
q4-2022xexhibit32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2023 Q1 Form 10-K Financial Statement

#000091447523000011 Filed on February 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2023 Q1 Form 10-K Financial Statement

#000091447523000011 Filed on February 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix